Abstract: Provided are methods of selecting a patient and/or treating a patient afflicted with high-grade serous epithelial that comprises upregulation of CDX2 and for autophagy inhibitor treatment. For example, the method of selecting a patient afflicted with a cancer likely to benefit from an autophagy inhibitor treatment, includes obtaining a biological sample; testing the biological sample for upregulated CDX2; and selecting the patient having a upregulated CDX2, as likely to benefit from and/or for treatment with the autophagy inhibitor treatment. Also provided are methods involving mutational status of p53.

Abstract: The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.

Abstract: The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.

Abstract: The present disclosure describes methods and compositions for diagnosing or predicting likelihood of a OSCC recurrence in a subject having undergone OSCC resection comprising: a) determining an expression level of one or more biomarkers selected from Table 4, 5 and/or 7, optionally MMP1, COL4A1, THBS2 and/or P4HA2 in a test sample from the subject, the one or more biomarkers comprising at least one of THBS2 and P4HA2, and b) comparing the expression level of the one or more biomarkers with a control, wherein a difference or a similarity in the expression level of the one or more biomarkers between the test sample and the control is used to diagnose or predict the likelihood of OSCC recurrence in the subject In particular, the present disclosure describes methods and compositions using a four-gene biomarker signature that can predict recurrence of oral squamous cell carcinoma in subjects that have histologically normal surgical resection margins.

Abstract: Illustrative embodiments provide a computer implemented method, a data processing system and a computer program product for scalable scheduling of tasks in heterogeneous systems is provided. According to one embodiment, the computer implemented method comprises fetching a set of tasks to form a received input, estimating run times of tasks, calculating average estimated completion times of tasks, producing a set of ordered tasks from the received input to form a task list, identifying a machine to be assigned, and assigning an identified task from the task list to an identified machine.

Abstract: The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.

Abstract: A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis.

Abstract: The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.

Abstract: Disclosed herein are methods and materials for prognosing survival of lung cancer patients, the methods comprising the detection of gains and losses of minimal common regions and/or genes associated with prognosis and benefit of chemotherapy.

Abstract: Provided is a gene expression signature consisting of 12 biomarkers for use in prognosing or classifying a subject with lung squamous cell carcinoma into a poor survival group or a good survival group. The 12-gene signature specific for squamous cell carcinoma consists of the biomarkers RPL22, VEGFA, G0S2, NES, TNFRSF25, DKFZP586P0123, COL8A2, ZNF3, PJPK5, RNFT2, ARHGEF12 and PTPN20A.

Abstract: There is provided a method for identifying a biomarker, such as a gene signature, associated with a biological parameter A 6-gene signature for non-small cell lung cancer (NSCLC) is also provided, as well as a method of prognosing or classifying a subject with non-small cell lung cancer into a poor survival group or a good survival group, using said gene signature

Abstract: The invention provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups. The invention also includes kits for use in the methods of the invention.

Abstract: The application provides methods of prognosing, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application.

Abstract: The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.

Abstract: The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.

Abstract: Illustrative embodiments provide a computer implemented method, a data processing system and a computer program product for scalable scheduling of tasks in heterogeneous systems is provided. According to one embodiment, the computer implemented method comprises fetching a set of tasks to form a received input, estimating run times of tasks, calculating average estimated completion times of tasks, producing a set of ordered tasks from the received input to form a task list, identifying a machine to be assigned, and assigning an identified task from the task list to an identified machine.

Abstract: The invention provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups. The invention also includes kits for use in the methods of the invention.

Abstract: A repository-based reverse engineering system for software systems and particularly legacy software systems. The reverse engineering system includes a graph-based data repository which holds data extracted from the source code in the software system. The graph-based data repository holds the data in a semi-structured form. The reverse engineering system includes mechanisms for constructing views on top of the extracted data and mechanisms for creating model abstractions on top of the views. The graph-based data repository provides flexible search and browse capabilities including pattern matching, structural searching, fuzzy and incomplete searching, and similarity-based searching. The system further includes an interface facility for external tools. The repository-based reverse engineering system enables integration of heterogeneous information sources, integration of external visualization and analytical tools, and searching and browsing facilities.

Abstract: A repository-based reverse engineering system for software systems and particularly legacy software systems. The reverse engineering system includes a graph-based data repository which holds data extracted from the source code in the software system. The graph-based data repository holds the data in a semi-structured form. The reverse engineering system includes mechanisms for constructing views on top of the extracted data and mechanisms for creating model abstractions on top of the views. The graph-based data repository provides flexible search and browse capabilities including pattern matching, structural searching, fuzzy and incomplete searching, and similarity-based searching. The system further includes an interface facility for external tools. The repository-based reverse engineering system enables integration of heterogeneous information sources, integration of external visualization and analytical tools, and searching and browsing facilities.